Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of carfilzomib at different
dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma,
Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor,
an enzyme responsible for degrading a wide variety of cellular proteins.